F-6/A

As filed with the U.S. Securities and Exchange Commission on June 14, 2021

Registration No. 333-256765

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM F-6/A

PRE-EFFECTIVE AMENDMENT NO. 1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

For Depositary Shares Evidenced by American Depositary Receipts

Ambrx Biopharma Inc.

(Exact name of issuer of deposited securities as specified in its charter)

n/a

(Translation of issuer’s name into English)

Cayman Islands

(Jurisdiction of incorporation or organization of issuer)

JPMORGAN CHASE BANK, N.A.

(Exact name of depositary as specified in its charter)

383 Madison Avenue, Floor 11, New York, New York 10179

Telephone (800) 990-1135

(Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)

Feng Tian, Ph.D.

President, Chief Executive Officer and Chairman of the Board of Directors

Ambrx Biopharma Inc.

10975 North Torrey Pines Road

La Jolla, California 92037

Telephone (858) 875-2400

(Address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

JPMorgan Chase Bank, N.A.
383 Madison Avenue, Floor 11

New York, NY 10179

Telephone: +1-800-990-1135

Scott R. Saks, Esq.

Troutman Pepper Hamilton Sanders LLP

875 Third Avenue

New York, NY 10022

Telephone: +1-212-808-2734

It is proposed that this filing become effective under Rule 466

☐ immediately upon filing

☐ on (Date) at (Time)

If a separate registration statement has been filed to register the deposited shares, check the following box. ☒

CALCULATION OF REGISTRATION FEE



Title of each class of Securities to be registered	Amount to be registered	Proposed maximum aggregate price per unit ⁽¹⁾	Proposed maximum aggregate offering price ⁽²⁾	Amount of registration fee⁽³⁾
American Depositary Shares evidenced by American Depositary Receipts, each American Depositary Share representing seven (7) ordinary shares, par value $0.0001 per share, of Ambrx Biopharma Inc.	100,000,000 American Depositary Shares	$0.05	$5,000,000	$545.50

(1)	Each unit represents one American Depositary Share.

(2)	Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of American Depositary Receipts evidencing American Depositary Shares.

(3)	Previously paid.

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

PART I

INFORMATION REQUIRED IN PROSPECTUS

The Prospectus consists of the proposed form of American Depositary Receipt (“ADR” or “American Depositary Receipt”) included as Exhibit A to the Deposit Agreement filed as Exhibit (a) to this Pre-Effective Amendment No. 1 to Registration Statement on Form F-6/A, which is incorporated herein by reference.

Item 1.

DESCRIPTION OF SECURITIES TO BE REGISTERED

CROSS REFERENCE SHEET


Item Number and Caption		Location in Form of American Depositary Receipt Filed Herewith as Prospectus

(1) Name and address of Depositary		Introductory paragraph and bottom of face of American Depositary Receipt

(2) Title of American Depositary Receipts and identity of deposited securities		Face of American Depositary Receipt, top center

Terms of Deposit:

(i) Amount of deposited securities represented by one unit of American Depositary Shares		Face of American Depositary Receipt, upper right corner

(ii) Procedure for voting, if any, the deposited securities		Paragraphs (6), (11) and (12)

(iii) Collection and distribution of dividends		Paragraphs (4), (5), (7) and (10)

(iv) Transmission of notices, reports and proxy soliciting material		Paragraphs (3), (8), (11) and (12)

(v) Sale or exercise of rights		Paragraphs (4), (5) and (10)

(vi) Deposit or sale of securities resulting from dividends, splits or plans of reorganization		Paragraphs (3), (4), (5), (10) and (13)

(vii) Amendment, extension or termination of the Deposit Agreement		Paragraphs (15), (16) and (17)

(viii)Rights of holders of ADRs to inspect the transfer books of the Depositary and the list of Holders of ADRs		Paragraph (3)

(ix) Restrictions upon the right to deposit or withdraw the underlying securities		Paragraphs (1), (2), (4), (5) and (6)

(x) Limitation upon the liability of the Depositary		Paragraph (14)

(3) Fees and Charges		Paragraph (7)

II-1

Item 2.

AVAILABLE INFORMATION


Item Number and Caption		Location in Form of American Depositary Receipt Filed Herewith as Prospectus
(b) Statement that Ambrx Biopharma Inc. is subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended, and, accordingly files certain reports with the Securities and Exchange Commission, and that such reports can be inspected by holders of American Depositary Receipts and copied through the EDGAR system or at public reference facilities maintained by the Securities and Exchange Commission in Washington, D.C.		Paragraph (8)

II-2

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 3.

EXHIBITS

(a)

Form of Deposit Agreement. Form of Deposit Agreement among Ambrx Biopharma Inc., JPMorgan Chase Bank, N.A., as depositary (the “Depositary”), and all holders and beneficial owners from time to time of American Depositary Receipts (“ADRs”) issued thereunder (the “Deposit Agreement”), including the Form of ADR attached as Exhibit A thereto. Filed herewith as Exhibit (a).

(b)

Any other agreement to which the Depositary is a party relating to the issuance of the American Depositary Shares registered hereunder or the custody of the deposited securities represented thereby. Not Applicable.

(c)

Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. Not Applicable.

(d)

Opinion of Troutman Pepper Hamilton Sanders LLP, counsel to the Depositary, as to the legality of the securities being registered. Previously filed.

(e)

Certification under Rule 466. Not applicable.

(f)

Powers of Attorney for certain officers and directors of the Company. Previously filed.

Item 4.

UNDERTAKINGS

(a)

The Depositary hereby undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of the American Depositary Receipts, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.

(b)

If the amounts of fees charged are not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an American Depositary Receipt thirty days before any change in the fee schedule.

II-3

SIGNATURE

Pursuant to the requirements of the Securities Act of 1933, as amended, JPMorgan Chase Bank, N.A. on behalf of the legal entity created by the Deposit Agreement, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Pre-Effective Amendment No. 1 to Registration Statement on Form 6/A to be signed on its behalf by the undersigned, thereunto duly authorized, in The City of New York, State of New York, on June 14, 2021.


Legal entity created by the form of Deposit Agreement for the issuance of ADRs evidencing American Depositary Shares

By: JPMORGAN CHASE BANK, N.A., as Depositary

By:		/s/ Gregory A. Leverdis
		Name: Gregory A. Leverdis
		Title: Executive Director

II-4

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, Ambrx Biopharma Inc. certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Pre-Effective Amendment No. 1 to Registration Statement on Form F-6/A to be signed on its behalf by the undersigned, thereunto duly authorized, in La Jolla, California, on June 14, 2021.


Ambrx Biopharma Inc.

By:		/s/ Feng Tian
		Name: Feng Tian
		Title: Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this Pre-Effective Amendment No. 1 to Registration Statement on Form F-6/A has been signed by the following persons in the capacities and on the dates indicated.


Signature	Title	Date

/s/ Feng Tian Feng Tian, Ph.D.	President, Chief Executive Officer and Chairman of the Board of Directors (Principal Executive and Financial Officer)	June 14, 2021

/s/ Dana Zhang Dana Zhang, C.P.A.	Vice President of Finance (Principal Accounting Officer)	June 14, 2021

* Xiaowei Chang, C.F.A.	Director	June 14, 2021

* Xiao Le	Director	June 14, 2021

* Chris Nolet, C.P.A.—Retired	Director	June 14, 2021

II-5


Signature	Title	Date

* Katrin Rupalla, Ph.D.	Director	June 14, 2021

* Olivia C. Ware, M.B.A.	Director	June 14, 2021


*By:	/s/ Feng Tian
	Name:	Feng Tian
		Attorney-in-Fact

II-6

SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF THE REGISTRANT

Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Ambrx Biopharma Inc., has signed this Pre-Effective Amendment No. 1 to Registration Statement on Form F-6/A in La Jolla, California, on June 14, 2021.


Authorized U.S. Representative FENG TIAN, PH.D.

By:		/s/ Feng Tian
		Name: Feng Tian
		Title: Chief Executive Officer

INDEX TO EXHIBITS


Exhibit Number

(a)		Form of Deposit Agreement among Ambrx Biopharma Inc., JPMorgan Chase Bank, N.A., as depositary (the “Depositary”), and all holders and beneficial owners from time to time of American Depositary Receipts (“ADRs”) issued thereunder, including the Form of ADR attached as Exhibit A thereto.